Search

everythinglearnresearchcommunity

for

Search:↓

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

A user is experiencing hair thinning and is using a peptide with oleanic acid as a DHT blocker, along with minoxidil, while waiting for topical finasteride. They plan to use a combination of minoxidil, finasteride, dermastamp, ketoconazole, and scalp massages, but are advised to stick to proven treatments like finasteride and minoxidil.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

OP is using 5% minoxidil and a foligain supplement for hair loss, with blood test results showing high cortisol levels. OP is considering starting finasteride, while another user shares their experience with finasteride and hair loss challenges due to malabsorption issues.

Fo-Ti is discussed as a potential treatment for hair loss, but its effectiveness is questioned. Users express skepticism and caution about its use.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The user discusses using Minoxidil for hair loss and is considering RU58841 to reduce excessive oil production. They seek advice on RU58841's effectiveness in blocking sebum production.

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

The user discusses using Follics FR5, FR10, and FR15, which combine Minoxidil, Adenosine, Procapil, Azelaic acid, and Procyanidin B2, to address hair loss. They have previously used Minoxidil, Finasteride, and Dutasteride with varying success.

Tazarotene's potential to enhance Minoxidil conversion, similar to Tretinoin, is questioned. Users discuss the lack of information and seek further details.

The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

Hair loss treatments like Minoxidil, finasteride, and potential mRNA therapies are discussed. There is skepticism about targeting specific genes due to the complex genetic nature of hair loss.

Researchers finding that microRNA can potentially regrow 90% of lost hair, and the challenges involved in moving this research forward to human trials. Various treatments for hair loss, such as finasteride and minoxidil, have been discussed.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

Injections of follistatin and growth factors can improve hair growth. Specific treatments discussed include Minoxidil, finasteride, and RU58841.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

Stemoxydine may work synergistically with minoxidil and finasteride for hair growth, but its effectiveness is debated, with some users experiencing minimal results and concerns about cost. Users suggest sticking to proven treatments like minoxidil and finasteride, while considering stemoxydine as an additional option.

PP405 is a new hair loss treatment targeting dormant hair follicles, with ongoing trials. Some users consider stopping finasteride and minoxidil to join trials, while others doubt its effectiveness.

Exploring different treatments for hair loss, such as cosmeRNA and HMI-115 which are small interference messenger RNA that inhibits the DHT receptor and an antibody that binds to the prolactin (PRL) receptor respectively; and researching mechanism and environment of hyperresponders.

PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.

Federal funding cuts have delayed PP405 research, affecting hair loss treatment progress, though clinical trials will continue. The discussion highlights PP405's potential compared to minoxidil and finasteride and stresses the importance of government-funded research.

Hair follicle stem cells remain in bald individuals, but progenitor cells do not, raising questions about hair regrowth claims by Pelage. PP405 is discussed as a potential treatment, with skepticism about its effectiveness compared to existing treatments like Minoxidil and Finasteride.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Genetic differences in hair follicles affect hair loss patterns. Treatments discussed include finasteride, dutasteride, minoxidil, and RU58841.

He Shou Wu (fo-ti) is discussed as a potential treatment for hair regrowth, with mixed opinions on its effectiveness. Some users report positive results, while others remain skeptical or have not noticed any changes.

The user does not respond well to minoxidil and is seeking an alternative to Tretinoin to upregulate sulfurtransferase activity for hair loss treatment. No specific alternative treatments were mentioned.